Unisol 5 mg/ml oral solution for piglets

国: アイルランド

言語: 英語

ソース: HPRA (Health Products Regulatory Authority)

有効成分:

Enrofloxacin

から入手可能:

Vetpharma Animal Health, S.L.

ATCコード:

QJ01MA90

INN（国際名）:

Enrofloxacin

投薬量:

5 milligram(s)/millilitre

医薬品形態:

Oral solution

処方タイプ:

POM: Prescription Only Medicine as defined in relevant national legislation

治療群:

Pigs

治療領域:

enrofloxacin

適応症:

Antibacterial

認証ステータス:

Authorised

承認日:

2009-07-10

製品の特徴

1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
UNISOL 5 mg/ml oral solution for piglets [ES, IE, PL, IT]
LANFLOX 0.5% oral solution for piglets [HU]
LANFLOX 5 mg/ml oral solution for piglets [PT]
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Enrofloxacin ................................................... 5.0
mg
EXCIPIENTS:
Oral solution. Aqueous, clear solution.
3.
CLINICAL INFORMATION
3.1.
TARGET SPECIES
Pigs (Piglets).
3.2.
INDICATIONS FOR USE FOR EACH TARGET SPECIES
In piglets (up to 10 kg):
-
Treatment of gastro-intestinal infection due to
_Escherichia coli_
.
To be used where clinical experience and/or sensitivity testing
indicates enrofloxacin as
the drug of choice.
3.3.
CONTRAINDICATIONS
Do not use when resistance / cross-resistance to (fluoro)quinolones is
known to occur in
the flock intended for treatment. Do not use in cases of known
hypersensitivity to the
active substance, other (fluoro)quinolones or to any of the
excipients.
Do not use in case of disturbances in growth of cartilage and/or
during injury of
locomotory system particularly on functionally loaded joints or due to
body weight
loaded joints.
QUALITATIVE
COMPOSITION OF EXCIPIENTS
AND OTHER CONSTITUENTS
QUANTITATIVE
COMPOSITION
IF THAT
INFORMATION IS ESSENTIAL
FOR PROPER
ADMINISTRATION OF THE VETERINARY
MEDICINAL PRODUC
t
_ _
Benzyl alcohol (E 1519)
14.0
mg
Potassium hydroxide
Hypromellose
Purified water
3.4.
SPECIAL WARNINGS
None.
3.5.
SPECIAL PRECAUTIONS FOR USE
Special precautions for safe use in the target species:
Do not use for prophylaxis.
Official and local antimicrobial policies should be taken into account
when the product is
used.
Fluoroquinolones should be reserved for the treatment of clinical
conditions which have
responded poorly, or are expected to respond poorly, to other classes
of antimicrobials.
Wherever possible, fluoroquinolones should only be used based on
susceptibility testing.
Use of the product deviating from instructions given in the SPC may
increase the
prevalence of bacteria resist